Oppenheimer Holdings' Bollinger Bands expand downward, indicating a bearish Marubozu pattern.

Based on the 15-minute chart provided by Oppenheimer Holdings, there has been a notable expansion of Bollinger Bands downward, coupled with the presence of a bearish Marubozu at 09:30 on September 30, 2025, at 11:00. This suggests that the current market trend is being primarily driven by sellers, indicating a lack of bullish momentum and a potential continuation of bearish sentiment.

Oppenheimer Holdings has recently revised its price target for Corbus Pharmaceuticals (NASDAQ:CRBP), lowering it to $53.00 from $60.00. This adjustment comes as Corbus prepares to present results from approximately 100 additional patients treated with its Nectin-4 targeting ADC, CRB-701, at the upcoming European Society for Medical Oncology (ESMO) conference. The presentation, scheduled for October 19, 2025, will focus on head and neck squamous cell carcinoma (HNSCC) and cervical cancer patients, comprising about 80 of the study participants. Despite the price target reduction, Oppenheimer remains optimistic about CRB-701’s potential to demonstrate a differentiated profile, highlighting that the ESMO presentation represents an important opportunity to strengthen both safety and efficacy datasets beyond the relatively small numbers reported to date Oppenheimer lowers Corbus Pharmaceuticals stock price target ahead of ESMO data^[1].

In other recent developments, Corbus Pharmaceuticals has received an FDA Fast Track Designation for its CRB-701, a Nectin-4-targeting antibody-drug conjugate intended for treating recurrent or metastatic head and neck squamous cell carcinoma. This designation comes after patients had previously undergone platinum-based chemotherapy and anti-PD(L)-1 therapy. Mizuho has reiterated its Outperform rating for Corbus Pharmaceuticals, maintaining a price target of $32.00. Additionally, Corbus Pharmaceuticals will present updated clinical data from its Phase 1/2 study of CRB-701 at the European Society for Medical Oncology Congress in October 2025. The presentation will cover results from trials involving patients with urothelial and non-urothelial solid tumors. In another development, Corbus has initiated the multiple ascending dose portion of its Phase 1 trial for CRB-913, aimed at treating obesity. This phase follows the single ascending dose portion completed earlier in the year, with no treatment-related neuropsychiatric events reported. These developments highlight Corbus Pharmaceuticals’ ongoing efforts in advancing its clinical trials and drug development pipeline Oppenheimer lowers Corbus Pharmaceuticals stock price target ahead of ESMO data^[1].